Treatment of adult short bowel syndrome with recombinant human growth hormone: A review of clinical studies

Bernard Messing, Sandra Blethen, John K. Dibaise, Laura E. Matarese, Ezra Steiger

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Extensive resection of the intestinal tract frequently results in inadequate digestion and/or absorption of nutrients, a condition known as short bowel syndrome (SBS). Several therapies, including parenteral nutrition (PN), bowel rehabilitation, and surgical procedures to reconstruct the bowel, have been used for patients with SBS. However, these treatments only partially correct the underlying problem of reduced bowel function in some patients. This review investigates the results of studies of recombinant human growth hormone (r-hGH) in patients with SBS. In one randomized, controlled and five open-label studies, treatment with r-hGH significantly increased absorption of energy, protein and/or carbohydrates. Four studies also demonstrated significantly increased body weight, lean body mass, total body potassium and/or total body water in response to r-hGH. However, in two other randomized controlled trials, r-hGH had no significant effect on energy or fluid absorption. In one randomized, controlled study and six open-label trials, treatment with r-hGH also allowed a majority of patients, including those with no colon and significant bowel resection, to eliminate or substantially reduce PN. Optimal clinical benefits appear to be achieved when r-hGH is administered in combination with a specialized oral diet and perhaps with glutamine. Although the use of r-hGH to treat SBS patients remains controversial, results from these studies suggest that short-term r-hGH treatment in combination with optimized medical and dietetic treatments can enhance bowel absorption and function and, with the continuation of optimized medical and dietetic treatments, may reduce PN requirements for a wide range of patients with SBS.

Original languageEnglish (US)
JournalJournal of Clinical Gastroenterology
Volume40
Issue numberSUPPL. 2
DOIs
StatePublished - May 2006

Fingerprint

Short Bowel Syndrome
Human Growth Hormone
Growth Hormone
Parenteral Nutrition
Dietetics
Therapeutics
Nutritional Requirements
Clinical Studies
Body Water
Glutamine
Digestion
Potassium
Colon
Rehabilitation
Randomized Controlled Trials
Body Weight
Carbohydrates
Diet
Food

Keywords

  • Clinical studies
  • Recombinant growth hormone
  • Short bowel syndrome

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Treatment of adult short bowel syndrome with recombinant human growth hormone : A review of clinical studies. / Messing, Bernard; Blethen, Sandra; Dibaise, John K.; Matarese, Laura E.; Steiger, Ezra.

In: Journal of Clinical Gastroenterology, Vol. 40, No. SUPPL. 2, 05.2006.

Research output: Contribution to journalArticle

Messing, Bernard ; Blethen, Sandra ; Dibaise, John K. ; Matarese, Laura E. ; Steiger, Ezra. / Treatment of adult short bowel syndrome with recombinant human growth hormone : A review of clinical studies. In: Journal of Clinical Gastroenterology. 2006 ; Vol. 40, No. SUPPL. 2.
@article{ec7524cbc14b41f8ae1ca2a7e580023c,
title = "Treatment of adult short bowel syndrome with recombinant human growth hormone: A review of clinical studies",
abstract = "Extensive resection of the intestinal tract frequently results in inadequate digestion and/or absorption of nutrients, a condition known as short bowel syndrome (SBS). Several therapies, including parenteral nutrition (PN), bowel rehabilitation, and surgical procedures to reconstruct the bowel, have been used for patients with SBS. However, these treatments only partially correct the underlying problem of reduced bowel function in some patients. This review investigates the results of studies of recombinant human growth hormone (r-hGH) in patients with SBS. In one randomized, controlled and five open-label studies, treatment with r-hGH significantly increased absorption of energy, protein and/or carbohydrates. Four studies also demonstrated significantly increased body weight, lean body mass, total body potassium and/or total body water in response to r-hGH. However, in two other randomized controlled trials, r-hGH had no significant effect on energy or fluid absorption. In one randomized, controlled study and six open-label trials, treatment with r-hGH also allowed a majority of patients, including those with no colon and significant bowel resection, to eliminate or substantially reduce PN. Optimal clinical benefits appear to be achieved when r-hGH is administered in combination with a specialized oral diet and perhaps with glutamine. Although the use of r-hGH to treat SBS patients remains controversial, results from these studies suggest that short-term r-hGH treatment in combination with optimized medical and dietetic treatments can enhance bowel absorption and function and, with the continuation of optimized medical and dietetic treatments, may reduce PN requirements for a wide range of patients with SBS.",
keywords = "Clinical studies, Recombinant growth hormone, Short bowel syndrome",
author = "Bernard Messing and Sandra Blethen and Dibaise, {John K.} and Matarese, {Laura E.} and Ezra Steiger",
year = "2006",
month = "5",
doi = "10.1097/01.mcg.0000212677.06549.80",
language = "English (US)",
volume = "40",
journal = "Journal of Clinical Gastroenterology",
issn = "0192-0790",
publisher = "Lippincott Williams and Wilkins",
number = "SUPPL. 2",

}

TY - JOUR

T1 - Treatment of adult short bowel syndrome with recombinant human growth hormone

T2 - A review of clinical studies

AU - Messing, Bernard

AU - Blethen, Sandra

AU - Dibaise, John K.

AU - Matarese, Laura E.

AU - Steiger, Ezra

PY - 2006/5

Y1 - 2006/5

N2 - Extensive resection of the intestinal tract frequently results in inadequate digestion and/or absorption of nutrients, a condition known as short bowel syndrome (SBS). Several therapies, including parenteral nutrition (PN), bowel rehabilitation, and surgical procedures to reconstruct the bowel, have been used for patients with SBS. However, these treatments only partially correct the underlying problem of reduced bowel function in some patients. This review investigates the results of studies of recombinant human growth hormone (r-hGH) in patients with SBS. In one randomized, controlled and five open-label studies, treatment with r-hGH significantly increased absorption of energy, protein and/or carbohydrates. Four studies also demonstrated significantly increased body weight, lean body mass, total body potassium and/or total body water in response to r-hGH. However, in two other randomized controlled trials, r-hGH had no significant effect on energy or fluid absorption. In one randomized, controlled study and six open-label trials, treatment with r-hGH also allowed a majority of patients, including those with no colon and significant bowel resection, to eliminate or substantially reduce PN. Optimal clinical benefits appear to be achieved when r-hGH is administered in combination with a specialized oral diet and perhaps with glutamine. Although the use of r-hGH to treat SBS patients remains controversial, results from these studies suggest that short-term r-hGH treatment in combination with optimized medical and dietetic treatments can enhance bowel absorption and function and, with the continuation of optimized medical and dietetic treatments, may reduce PN requirements for a wide range of patients with SBS.

AB - Extensive resection of the intestinal tract frequently results in inadequate digestion and/or absorption of nutrients, a condition known as short bowel syndrome (SBS). Several therapies, including parenteral nutrition (PN), bowel rehabilitation, and surgical procedures to reconstruct the bowel, have been used for patients with SBS. However, these treatments only partially correct the underlying problem of reduced bowel function in some patients. This review investigates the results of studies of recombinant human growth hormone (r-hGH) in patients with SBS. In one randomized, controlled and five open-label studies, treatment with r-hGH significantly increased absorption of energy, protein and/or carbohydrates. Four studies also demonstrated significantly increased body weight, lean body mass, total body potassium and/or total body water in response to r-hGH. However, in two other randomized controlled trials, r-hGH had no significant effect on energy or fluid absorption. In one randomized, controlled study and six open-label trials, treatment with r-hGH also allowed a majority of patients, including those with no colon and significant bowel resection, to eliminate or substantially reduce PN. Optimal clinical benefits appear to be achieved when r-hGH is administered in combination with a specialized oral diet and perhaps with glutamine. Although the use of r-hGH to treat SBS patients remains controversial, results from these studies suggest that short-term r-hGH treatment in combination with optimized medical and dietetic treatments can enhance bowel absorption and function and, with the continuation of optimized medical and dietetic treatments, may reduce PN requirements for a wide range of patients with SBS.

KW - Clinical studies

KW - Recombinant growth hormone

KW - Short bowel syndrome

UR - http://www.scopus.com/inward/record.url?scp=33745307348&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745307348&partnerID=8YFLogxK

U2 - 10.1097/01.mcg.0000212677.06549.80

DO - 10.1097/01.mcg.0000212677.06549.80

M3 - Article

C2 - 16770166

AN - SCOPUS:33745307348

VL - 40

JO - Journal of Clinical Gastroenterology

JF - Journal of Clinical Gastroenterology

SN - 0192-0790

IS - SUPPL. 2

ER -